Form 4: Director Jaewon Ryu Receives Privia Health Equity Grant

Director Jaewon Ryu was granted 8,463 restricted stock units in Privia Health Group, Inc. as part of the company's 2021 Omnibus Incentive Plan.

Summary

• Director Jaewon Ryu acquired 8,463 restricted stock units (RSUs) on May 20, 2026.
• The grant was issued under the Privia Health Group, Inc. 2021 Omnibus Incentive Plan.
• Following this transaction, the reporting person's total beneficial ownership of common stock increased to 47,110 shares.
• The RSUs were granted at a price of $0 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standard incentive structure utilized to retain board leadership.

Negatives

• None identified in this filing.

Risks

• Vesting of equity is subject to the company's 2027 annual meeting timeline or the first anniversary of the grant date.

Future Outlook

The restricted stock units are scheduled to vest on the earlier of the day before the 2027 annual meeting of stockholders or the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the healthcare services sector to ensure board alignment with company performance and shareholder interests.

Comparison to Industry Standards

• The use of restricted stock units for director compensation is consistent with standard practices for mid-cap healthcare companies.
• The vesting schedule aligns with typical one-year cliff or annual meeting-based vesting cycles observed in the industry.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity incentive grant.

Next Steps

• Vesting of the 8,463 restricted stock units on or before May 20, 2027.

Key Dates

Keywords

Privia Health Group, PRVA, Form 4, Insider Trading, Equity Compensation, Director Compensation